Please login to the form below

Not currently logged in
Email:
Password:

rituximab

This page shows the latest rituximab news and features for those working in and with pharma, biotech and healthcare.

Celgene’s Revlimid gets a win in late-stage lymphoma

Celgene’s Revlimid gets a win in late-stage lymphoma

The AUGMENT trial paired Revlimid (lenalidomide) with Roche’s established lymphoma therapy Rituxan (rituximab) in patient with two types of NHL – follicular lymphoma (FL) and marginal zone lymphoma (MZL) – and showed

Latest news

More from news
Approximately 9 fully matching, plus 131 partially matching documents found.

Latest Intelligence

  • The sound of silence puts the squeeze on generics and biosimilars The sound of silence puts the squeeze on generics and biosimilars

    drugs - from Adalimumab to Rituximab - go off-patent and boost savings across eight European nations to 33.4bn over the next three years.

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Canada for biosimilar versions of Rituxan (rituximab) and Herceptin (trastuzumab).

  • Deal Watch December 2016 Deal Watch December 2016

    Sanofi's payments to JHL, the Taiwanese manufacturer of a rituximab biosimilar, total $101m upfront for the China market alone; 30% of the headline figure.

  • Deal Watch November 2016 Deal Watch November 2016

    By destroying B cells, rituximab is used to treat diseases characterised by excessive numbers of B cells, overactive B cells or dysfunctional B cells including many lymphomas, leukaemias, transplant rejection and ... In May this year Sandoz announced

  • Deal Watch October 2016 Deal Watch October 2016

    Teva has paid $160m upfront with $60m refundable or creditable (presumably if registration fails) for rituximab (Rituxan) and trastuzumab (Herceptin), both in late phase III development. ... 175. Celltrion (SK). Teva (IS). Co-commercialisation.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • ImmunoGen hires VP product strategy ImmunoGen hires VP product strategy

    His previous business experience includes several oncology-related positions at Biogen Idec, including team leader for Rituxan (rituximab), as well as commercial positions at Amgen,.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • The Biosimilar Challenge

    Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).

  • Biosimilars: Getting the flock to market

    The greatest attraction, naturally, is high-revenue anti-TNF agents like MabThera (rituximab) and Humira (adalimumab), for many years the world's most valuable drug.

  • The Biosimilar Challenge

    Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics